BioRestorative Therapies Presents New Preclinical Data at ISCT 2026 Highlighting Source-Specific Exosome Functionality and Commercial Applications in BioCosmeceuticals

Data demonstrate distinct functional signatures across MSC-derived extracellular vesicles supporting targeted regenerative and aesthetic applications MELVILLE, N. Y. , May 13, 2026 (GLOBE NEWSWIRE) -- BioRestorative Therapies, Inc. ("BioRestorative," "BRTX," or the "Company") (Nasdaq: BRTX), a late-stage clinical regenerative medicine company focused on stem cell-based therapies and products, today announces the presentation of new preclinical data at the International Society for Cell and Gene Therapy (ISCT) 2026 Annual Meeting, which took place May 6-9 in Dublin, Ireland.